Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/33037
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yurdacan, Beste | - |
dc.contributor.author | Eskiler, Gamze Güney | - |
dc.date.accessioned | 2023-06-14T12:41:23Z | - |
dc.date.available | 2023-06-14T12:41:23Z | - |
dc.date.issued | 2019-07 | - |
dc.identifier.citation | Yurdacan, B. vd. (2019). ''Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid''. Journal of Pharmacy and Pharmacology, 71(7), 1119-1132. | en_US |
dc.identifier.issn | 0022-3573 | - |
dc.identifier.issn | 2042-7158 | - |
dc.identifier.uri | https://doi.org/10.1111/jphp.13097 | - |
dc.identifier.uri | https://academic.oup.com/jpp/article/71/7/1119/6122173 | - |
dc.identifier.uri | http://hdl.handle.net/11452/33037 | - |
dc.description.abstract | Objectives Sorafenib (SOR) is an orally administered molecular targeted agent in the systemic chemotherapy of hepatocellular carcinoma (HCC). However, the partial response of SOR is limited due to its adverse side effect and high heterogeneity and resistant phenotype of HCC. In the current study, we investigated synergistic effects of SOR and usnic acid (UA) on HCC cell lines including HepG2 and SNU-449, and a normal cell line, HUVEC. Methods The antiproliferative and apoptotic effects of combination therapy and SOR alone were analysed by WST-1 and Annexin V analysis, respectively. Furthermore, cell cycle, gene expression analysis of SOR-targeted kinases and acridine orange-ethidium bromide staining were also performed in combined treatments. Key findings Our results demonstrated that SOR and UA combination indicated a strong synergism in HCC cell lines and reduced SOR toxicity in HUVEC cells. Additionally, the combination treatment SOR and UA significantly induced much more apoptotic cell death and G0/G1 arrest through downregulation of SOR-targeted kinases. Conclusions Consequently, SOR and UA combination could be a new therapeutic strategy for HCC treatment. | tr_TR |
dc.language.iso | en | en_US |
dc.publisher | Oxford University | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Combination treatment | en_US |
dc.subject | Hepatocellular carcinoma | en_US |
dc.subject | Sorafenib | en_US |
dc.subject | Usnic acid | en_US |
dc.subject | Antitumor-activity | en_US |
dc.subject | Cancer-cells | en_US |
dc.subject | Inhibition | en_US |
dc.subject | Pathway | en_US |
dc.subject | Gene | en_US |
dc.subject | P16 | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject.mesh | Annexin A5 | en_US |
dc.subject.mesh | Antineoplastic Agents | en_US |
dc.subject.mesh | Apoptosis | en_US |
dc.subject.mesh | Benzofurans | en_US |
dc.subject.mesh | Carcinoma, Hepatocellular | en_US |
dc.subject.mesh | Cell Line, Tumor | en_US |
dc.subject.mesh | Cell Proliferation | en_US |
dc.subject.mesh | Drug Synergism | en_US |
dc.subject.mesh | Drug Therapy, Combination | en_US |
dc.subject.mesh | Hep G2 Cells | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Liver Neoplasms | en_US |
dc.subject.mesh | Protein-Tyrosine Kinases | en_US |
dc.subject.mesh | Sorafenib | en_US |
dc.title | Investigation of new treatment option for hepatocellular carcinoma: A combination of sorafenib with usnic acid | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000470977400010 | tr_TR |
dc.identifier.scopus | 2-s2.0-85065044797 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri/Tıbbi Biyoloji Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0002-1619-6680 | tr_TR |
dc.contributor.orcid | 0000-0002-3820-424X | tr_TR |
dc.contributor.orcid | 0000-0002-3316-316X | tr_TR |
dc.contributor.orcid | 0000-0002-3316-316X | tr_TR |
dc.contributor.orcid | 0000-0001-7904-883X | tr_TR |
dc.identifier.startpage | 1119 | tr_TR |
dc.identifier.endpage | 1132 | tr_TR |
dc.identifier.volume | 71 | tr_TR |
dc.identifier.issue | 7 | tr_TR |
dc.relation.journal | Journal of Pharmacy and Pharmacology | en_US |
dc.contributor.buuauthor | Egeli, Ünal | - |
dc.contributor.buuauthor | Eryılmaz, Işıl Ezgi | - |
dc.contributor.buuauthor | Çeçener, Gülşah | - |
dc.contributor.buuauthor | Tunca, Berrin | - |
dc.contributor.researcherid | ABI-6078-2020 | tr_TR |
dc.contributor.researcherid | AAP-9988-2020 | tr_TR |
dc.contributor.researcherid | GWV-3548-2022 | tr_TR |
dc.contributor.researcherid | AAH-1656-2021 | tr_TR |
dc.contributor.researcherid | AAH-1420-2021 | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.identifier.pubmed | 31025377 | tr_TR |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 55665145000 | tr_TR |
dc.contributor.scopusid | 57189380840 | tr_TR |
dc.contributor.scopusid | 6508156530 | tr_TR |
dc.contributor.scopusid | 6602965754 | tr_TR |
dc.subject.scopus | Usnic Acid; Extract; Lichen (Disease) | en_US |
dc.subject.emtree | Acridine orange | en_US |
dc.subject.emtree | Ethidium bromide | en_US |
dc.subject.emtree | Lipocortin 5 | en_US |
dc.subject.emtree | Phosphotransferase | en_US |
dc.subject.emtree | Sorafenib | en_US |
dc.subject.emtree | Usnic acid | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Benzofuran derivative | en_US |
dc.subject.emtree | Protein tyrosine kinase | en_US |
dc.subject.emtree | Antiproliferative activity | en_US |
dc.subject.emtree | Apoptosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Autophagy | en_US |
dc.subject.emtree | Cell cycle arrest | en_US |
dc.subject.emtree | Cell organelle | en_US |
dc.subject.emtree | Cell structure | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Down regulation | en_US |
dc.subject.emtree | Drug cytotoxicity | en_US |
dc.subject.emtree | Drug potentiation | en_US |
dc.subject.emtree | Gene expression | en_US |
dc.subject.emtree | Hep-G2 cell line | en_US |
dc.subject.emtree | Hepatocellular carcinoma cell line | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | HUVEC cell line | en_US |
dc.subject.emtree | Liver cell carcinoma | en_US |
dc.subject.emtree | Percentage of cells in G0/G1 phase | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Cell proliferation | en_US |
dc.subject.emtree | Combination drug therapy | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Liver cell carcinoma | en_US |
dc.subject.emtree | Liver tumor | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Tumor cell line | en_US |
Appears in Collections: | Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Egeli_vd_2019.pdf | 3 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License